Cancer Family
Oral Neoplasm
CI-CAN-00000301Explore in graph →
Non-malignant163 active trials2 evidence items
- NCIt
- C8989
Loading cancer entity…
Cancer Family
CI-CAN-00000301Explore in graph →
Clinical trials
604 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06636734 | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07400094 | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC(NeoCamre-HN) | not yet recruiting | Phase 2 | 50 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER |
| 1 |
| Feb 10, 2026 |
| clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | active not recruiting | Phase 2 | 36 | Emory UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05312710 | Safety and Efficacy of APG-157 in Head and Neck Cancer | active not recruiting | Phase 2 | 24 | Aveta Biomics, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07346807 | Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer | not yet recruiting | Phase 2 | 69 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07254962 | CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)(CAPTURE) | not yet recruiting | Phase 2 | 75 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT03021993 | Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer | completed | Phase 2 | 17 | Medical University of South CarolinaOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02882282 | Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT03383094 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | active not recruiting | Phase 2 | 126 | Loren Mell, MDOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07079410 | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04330781 | Radiotherapy of Head and Neck Cancer Using an Intraoral Stent | completed | Phase 2 | 220 | Oslo University HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03854032 | Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 45 | Thomas Jefferson UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06009861 | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | active not recruiting | Phase 2 | 110 | Peking University Hospital of StomatologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06848439 | Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer | not yet recruiting | Phase 2 | 26 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06965738 | Buccal Fat for Transoral Robotic Lateral Oropharyngectomy Defects to and Postoperative Pain(BOLT) | not yet recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06861712 | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03342911 | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | completed | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06728631 | Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL | active not recruiting | Phase 2 | 22 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 2 | 13 | University of UtahOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06819605 | Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma(NETCAM-RCT) | not yet recruiting | Phase 2 / Phase 3 | 46 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Feb 11, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06653517 | Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma(NETCAM) | recruiting | Phase 2 | 12 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | completed | Phase 2 / Phase 3 | 60 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03181035 | Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer(FAITH) | suspended | Phase 1 / Phase 2 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02367859 | Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | completed | Phase 2 | 1 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT02285543 | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients | terminated | Phase 2 | 10 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02290145 | Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06130332 | Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) | recruiting | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT01914900 | Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | completed | Phase 2 | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials